文献速递头颈外科

头颈癌患者的抑郁症状、全身性炎症与生存

Depressive Symptoms, Systemic Inflammation, and Survival Among Patients With Head and Neck Cancer.
PubMed 文献 · JAMA Otolaryngol Head Neck Surg · 2024-01-01

这项前瞻性观察队列研究纳入394例头颈癌患者,评估治疗前抑郁症状、全身性炎症与治疗后肿瘤反应对总生存的中介通路。结果显示抑郁与炎症均与早期死亡相关,抑郁-生存关联完全由炎症中介,肿瘤反应部分中介该关联。

要点

  • 治疗前PHQ-9抑郁症状与全身性炎症指数升高相关(部分r=0.168;95%CI 0.007-0.038)。
  • PHQ-9(HR 1.04;95%CI 1.02-1.07)与SII(HR 1.36;95%CI 1.08-1.71)均与早期死亡相关。
  • 抑郁-生存关联完全由炎症中介(HR 1.28;95%CI 1.00-1.64),部分由肿瘤反应中介(HR 9.44;95%CI 6.23-14.32)。

核心结论

  • 全身性炎症是抑郁与死亡关联的新候选机制,肿瘤反应部分中介抑郁对死亡的影响。
  • 即使治疗计划阶段轻度抑郁症状也可能与更高全身性炎症、更差肿瘤反应及生存结局相关,因此抑郁应在临床上予以处理。

研究设计与样本

  • 前瞻性观察队列研究,纳入2013年5月10日至2019年12月30日在一家多学科头颈癌诊所治疗并随访2年的头颈癌患者。
  • 共394例患者(平均[SD]年龄62.5[11.5]岁;277例[70.3%]男性)。
  • 数据分析于2022年6月29日至2023年6月23日进行。

主要发现

  • 285例(72.3%)PHQ-9评分低于抑郁临床界值,其抑郁症状与炎症显著相关(部分r=0.168;95%CI 0.007-0.038)。
  • 抑郁与炎症均与早期死亡相关:PHQ-9 HR 1.04(95%CI 1.02-1.07);SII HR 1.36(95%CI 1.08-1.71)。
  • 抑郁-生存关联完全由炎症中介(HR 1.28;95%CI 1.00-1.64)。
  • 抑郁症状与更差肿瘤反应相关(OR 1.05;95%CI 1.01-1.08),抑郁-生存关联部分由肿瘤反应中介(HR 9.44;95%CI 6.23-14.32)。
  • 全身性炎症与肿瘤反应无关联。

临床怎么用

  • 作者认为,即使治疗计划阶段轻度抑郁症状也可能与更高全身性炎症、更差肿瘤反应及生存结局相关,因此抑郁应在临床上予以处理。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Patients with head and neck cancer experience high rates of depression. Depression and systemic inflammation have been found to be associated in numerous cancer types, often independently from disease status. Depression-related inflammation may elevate the risks for poor tumor response to treatment and early mortality, and comprises a mechanism by which depression is associated with survival in head and neck cancer. OBJECTIVE: To assess mediation pathways incorporating pretreatment depressive symptoms, pretreatment inflammation, and tumor response posttreatment on overall survival among patients with head and neck cancer. DESIGN, SETTING, AND PARTICIPANTS: This was a prospective observational cohort study of patients with head and neck cancer treated in a single multidisciplinary head and neck cancer clinic from May 10, 2013, to December 30, 2019, and followed up for 2 years. Data analysis was performed from June 29, 2022, to June 23, 2023. EXPOSURES: Patient-reported depressive symptoms using the Patient Health Questionnaire-9 item (PHQ-9) at treatment planning; pretreatment hematology workup for systemic inflammation index (SII) score; and clinical data review for tumor response (complete vs incomplete) and overall survival. MAIN OUTCOMES: Two-year overall survival. RESULTS: The total study cohort included 394 patients (mean [SD] age, 62.5 [11.5] years; 277 [70.3%] males) with head and neck cancer. Among 285 patients (72.3%) who scored below the clinical cutoff for depression on the PHQ-9, depressive symptoms were significantly associated with inflammation (partial r, 0.168; 95% CI, 0.007-0.038). In addition, both depression and inflammation were associated with early mortality (PHQ-9: hazard ratio [HR], 1.04; 95% CI, 1.02-1.07; SII: HR, 1.36; 95% CI, 1.08-1.71). The depression-survival association was fully mediated by inflammation (HR, 1.28; 95% CI, 1.00-1.64). Depressive symptoms were also associated with poorer tumor response (odds ratio, 1.05; 95% CI, 1.01-1.08), and the depression-survival association was partially mediated by tumor response (HR, 9.44; 95% CI, 6.23-14.32). Systemic inflammation was not associated with tumor response. CONCLUSIONS: In this cohort study, systemic inflammation emerged as a novel candidate mechanism of the association of depression with mortality. Tumor response partially mediated effects of depression on mortality, replicating prior work. Thus, depression stands out as a highly feasible target for renewed clinical attention. Even mild symptoms of depression during the treatment-planning phase may be associated with higher systemic inflammation in addition to poorer tumor response to treatment and survival outcomes; therefore, depression should be clinically addressed.

来源:JAMA Otolaryngol Head Neck Surg,查看原文。版权归原作者所有。

引用

  1. Cash E, Albert C, Palmer I, et al. Depressive Symptoms, Systemic Inflammation, and Survival Among Patients With Head and Neck Cancer. JAMA Otolaryngol Head Neck Surg. 2024. PMID: 38546616. doi:10.1001/jamaoto.2024.0231

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。